Acute Myeloid Leukemia Coverage From Every Angle

Allogeneic HCT for AML: Long-Term Follow-up for Late Morbidities

By: Kayci Reyer
Posted: Tuesday, March 2, 2021

Research presented as correspondence in the American Journal of Hematology reported the “cost of long-term survival” for childhood survivors of acute myeloid leukemia (AML) who underwent allogeneic hematopoietic cell transplantation (allo-HCT) during first or second remission. Henrik Hasle, MD, of Aarhus University Hospital in Denmark, and colleagues compared hospitalizations rates among childhood survivors who underwent allo-HCT, childhood survivors who did not undergo allo-HCT, and the general population in Scandinavia.

“Our findings underline the necessity of long‐term follow‐up after allo-HCT that facilitates early detection of late morbidities and targeted lifestyle and medical interventions regardless of which conditioning regimen is used,” concluded the study authors.

The study included all 5-year survivors of childhood AML who had been diagnosed between July 1, 1984, and December 31, 2005, in Denmark, Finland, Iceland, or Sweden (n = 196), as well as a cohort from the general population with similar sex, age, and nationality (n = 152,231). Almost half (49%) of the childhood survivors had undergone allo-HCT; the remaining 51% had undergone chemotherapy alone. The median follow-up was 12 years after diagnosis for those receiving allo-HCT and 11 years after diagnosis for those receiving chemotherapy. A total of 61% of survivors who received allo-HCT had also been given total-body irradiation, and 38% had received allo-HCT in second complete remission.

Almost one-third of the survivor cohort had experienced at least one hospitalization for a somatic disease. A total of 36% of those who had undergone allo-HCT had been hospitalized at least once, with survivors receiving transplants during second complete remission with the highest rate (49%). Survivors who had received chemotherapy had a comparable hospitalization rate to the general population. Those undergoing allo-HCT during first complete remission experienced an increased hospitalization risk for endocrine, cardiovascular, respiratory, gastrointestinal, and digestive diseases, whereas those undergoing allo-HCT during second complete remission had an increased hospitalization risk for infectious disease and nervous system; bone, joints, and soft tissue; respiratory; gastrointestinal and digestive; and endocrine diseases.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.